3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
104
Colorectal Neoplasms
63
Stomach Neoplasms
49
Rectal Neoplasms
42
Colonic Neoplasms
24
Neoplasm Metastasis
21
Nasopharyngeal Carcinoma
19
Triple Negative Breast Neoplasms
18
Pancreatic Neoplasms
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Neoplasms
12
Gallbladder Neoplasms
7
Cholangiocarcinoma
7
Adenocarcinoma
6
Esophageal Neoplasms
5
Biliary Tract Neoplasms
5
Adenocarcinoma Of Esophagus
5
Esophageal Squamous Cell Carcinoma
4
Neuroendocrine Tumors
3
Gastrointestinal Neoplasms
3
Digestive System Neoplasms
3
Bile Duct Neoplasms
3
Recurrence
2
Pathologic Complete Response
2
Liver Neoplasms
2
Intestinal Neoplasms
2
Hand-Foot Syndrome
2
HER2-positive Advanced Breast Cancer
2
HER2 Positive Metastatic Breast Cancer
2
Drug-Related Side Effects and Adverse Reactions
2
Interventions
Gemcitabine
11
Cisplatin
11
Radiotherapy, Intensity-Modulated
6
tislelizumab
2
nimotuzumab
2
camrelizumab
2
Fluorouracil
2
Carboplatin
2
spartalizumab
1
sintilimab
1
sargramostim
1
pembrolizumab
1
fosaprepitant
1
etoposide phosphate
1
Tropisetron
1
Radiotherapy
1
Induction Chemotherapy
1
Ifosfamide
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Chemotherapy, Adjuvant
1
Chemoradiotherapy
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Nasopharyngeal Neoplasms
×
Capecitabine
×
Clear all
NCT02611960
2023-07-13
Keynote-122
Merck Sharp & Dohme LLC
Phase 3
Completed
233 enrolled
21 charts